

Recipients of the AACR's Scholar-in-Training Awards and Grants for the 96th Annual Meeting, Anaheim, California

AACR Scholar-in-Training Awards for Early-Career Scientists

AACR's highly competitive Scholar-in-Training Awards provide financial support for predoctoral students, medical students and residents, postdoctoral and clinical fellows or the equivalent attending an AACR Annual Meeting, Special Conference, or other AACR-sponsored scientific meeting.

Selection of these recipients was based upon the scientific merit of the proffered papers and was made by the members of the AACR's prestigious Program Committee. The Awards will provide these outstanding scientists with an opportunity to share their research findings with the international cancer research community, gain valuable experience, receive feedback on their research, and develop new collaborations with colleagues in their field. Several awards are restricted to specific fields of research or to presenters from selected areas of the world; these restrictions are noted below.

The Board of Directors of the AACR expresses its appreciation to the generous sponsors of these awards and extends congratulations to these outstanding scholars.

AACR-Gerald B. Grindey Scholar-in-Training Award

For a meritorious proffered paper in the field of preclinical science.

Abstract # 2564, Neil D. Gross, M.D., Memorial Sloan-Kettering Cancer Center, New York, NY, USA, *Jun N-terminal kinase: A potential target for the treatment of head and neck squamous cell carcinoma (HNSCC)*

AACR-Gary J. Miller Memorial Scholar-in-Training Award

For a meritorious proffered paper directly related to prostate cancer research.

Abstract # 911, Yipeng Wang, M.D., Ph.D., Sidney Kimmel Cancer Center, San Diego, CA, USA, *Survey of differentially methylated promoters in prostate cancer cell lines*

AACR-AFLAC, Incorporated Scholar-in-Training Awards

For Associate Members of the AACR.

Abstract # 885, Antoine M. Snijders, Ph.D., University of California, San Francisco, CA, USA, *Demonstration of oral squamous cell carcinoma second primary clonality using genome wide array comparative genomic hybridization*

Abstract # 903, Shaoxi Liao, M.D., Ph.D., Duke University Medical Center, Durham, NC, USA, *Digital karyotyping identifying OTX2 as a medulloblastoma oncogene, whose product can be targeted by retinoic acid*

Abstract # 905, David S. Shames, B.A., UT Southwestern Medical Center, Dallas, TX, USA, *A genome-wide screen for methylated genes in lung cancer using 5-aza-2'-deoxycytidine treatment and parallel analysis of gene expression and genomic profiling*

Abstract # 1617, David M. Weinstock, M.D., Memorial Sloan-Kettering Cancer Center, New York, NY, USA, *Chromosomal translocations between nonhomologous sequences occur primarily through microhomology-mediated end-joining: A model of oncogenic translocations*

Abstract # 1623, Patrick S. Lin, Ph.D., Stanford University, Stanford, CA, USA, *The role of the Rb/E2F tumor suppressor pathway in DNA damage repair*

Abstract # 1625, Jan Theys, Ph.D., University of Maastricht, Maastricht, The Netherlands, *Role of ubiquitin K63 linkages in DNA damage repair*

Abstract # 1654, Dong Wook Kim, M.D., Ph.D., Vanderbilt University Medical Center, Nashville, TN, USA, *Increased tumor control is achieved by optimizing schedule of administration of radiation mediated vasculytic therapy based on noninvasively measured physiologic response parameters*

Abstract # 1655, Chun-Chieh Wang, M.D., University of California, Los Angeles, CA, USA, *HDJ-2 is an important target of farnesyltransferase inhibitor, R115777, induced radiosensitization*

Abstract # 1656, Simone Fulda, M.D., University Children's Hospital, Ulm, Germany, *Sensitization for gamma-irradiation-induced apoptosis by Smac agonists*

Abstract # 1682, Xiaojun Liu, Ph.D., UT M.D. Anderson Cancer Center, Houston, TX, USA, *Abrogation of S-phase and G2 cell cycle checkpoints by small molecule inhibitors of the DNA damage kinase, Chk1*

Abstract # 1702, Charles N. Landen, Jr., M.D., UT M.D. Anderson Cancer Center, Houston, TX, USA, *Therapeutic silencing of EphA2 by in vivo liposomal siRNA delivery*

Abstract # 2111, Yelena Margolin, B.S., Massachusetts Institute of Technology, Cambridge, MA, USA, *Sequence dependent guanine oxidation by nitrosoperoxy carbonate violates the rules of charge migration in DNA*

Abstract # 2516, Konstantin Stoletov, Ph.D., The Scripps Research Institute, La Jolla, CA, USA, *High resolution imaging of human tumor formation and angiogenesis in a novel Zebrafish model*

Abstract # 2525, Monica M. Richert, Ph.D., University of Alabama at Birmingham, Birmingham, AL, USA, *Breast cancer metastasis to lung and bone is decreased by difluoromethylornithine treatment*

Abstract # 2533, Casey E. Bohl, B.S., The Ohio State University, Columbus, OH, USA, *The crystal structure of the androgen receptor W741L mutant ligand binding domain bound to R-bicalutamide*

Abstract # 2555, Veronica Wendy Setiawan, Ph.D., University of Southern California, Los Angeles, CA, USA, *A comprehensive haplotype analysis of IGF-1 and breast cancer risk: The Multiethnic Cohort*

Abstract # 2559, Rayjean J. Hung, Ph.D., International Agency for Research on Cancer, Lyon, France, *Multigenic investigation of sequence variants in DNA repair and cell cycle control pathways on risk of lung cancer*

Abstract # 2566, Sami Sarfaraz, Ph.D., University of Wisconsin, Madison, WI, USA, *Cannabinoid receptors: A novel target for the treatment of prostate cancer*

Abstract # 2582, Beatrice Bohl, Ph.D., The Burnham Institute, La Jolla, CA, USA, *Mice lacking bi-1 gene demonstrate accelerated liver regeneration*

Abstract # 2583, Toru Fukushima, M.D., Ph.D., The Burnham Institute, La Jolla, CA, USA, *Critical function for p53-induced beta-Catenin degradation at G1 checkpoint during cell cycle progression*

Abstract # 2587, Petra den Hollander, M.S., UT M.D. Anderson Cancer Center, Houston, TX, USA, *A dynein motor protein making inroads into the cell cycle deregulation and breast cancer*

Abstract # 2643, Qing Chen, Ph.D., H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, *Targeting the Fanconi Anemia/BRCA DNA interstrand crosslink repair pathway to overcome melphalan resistance in multiple myeloma cells*

Abstract # 2651, Tonya C. Walser, B.S., University of Maryland School of Medicine, Baltimore, MD, USA, *Chemokine-targeted therapies in a model of metastatic breast cancer*

Abstract # 2658, Jennifer B. Jacob, Ph.D., Wayne State University, Detroit, MI, USA, *Regulatory T cell status and MHC II haplotypes determine the balance between overcoming HER2 tolerance by vaccination and inducing autoimmune thyroiditis*

Abstract # 2659, Guobin He, M.S., UT M.D. Anderson Cancer Center, Smithville, TX, USA, *Thiazolidinedione, a class of insulin sensitizers, strongly inhibits IGF-1 mitogenic signaling*

Abstract # 2668, Po-Lin So, Ph.D., University of California, San Francisco, CA, USA, *Analysis of the mechanism of the chemopreventive efficacy of tazarotene against cutaneous basal cell carcinoma in Ptch1 +/- mice*

Abstract # 2739, Michael J. Boland, B.S., University of Nebraska, Omaha, NE, USA, *A novel interaction between thymine DNA-glycosylase and the de novo methyltransferase, Dnmt3b*

Abstract # 2818, Eriko Michishita, Ph.D., National Cancer Institute, Bethesda, MD, USA, *Characterization and investigation of seven SIRT proteins in human cell aging: Down-regulation of SIRT1 extends cellular lifespan*

Abstract # 3209, Shelley S. Tworoger, Ph.D., Harvard School of Public Health, Boston, MA, USA, *Association between plasma prolactin concentrations and subsequent risk of premenopausal breast cancer*

Abstract # 4112, Nicola Frances Smith, Ph.D., National Cancer Institute, Bethesda, MD, USA, *Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel*

Abstract # 4317, Roland Chiu, Ph.D., University of Maastricht, Maastricht, The Netherlands, *Isolation and biochemical characterization of ubiquitin K63 targets in mammalian cells*

Abstract # 4390, Vandana B. Sharma, M.D., Ph.D., Stanford University, Palo Alto, CA, USA, *Chemosensitivity and DNA repair in BRCA1 deficient murine mammary epithelial cells*

Abstract # 4470, Ju-Seog Lee, Ph.D., National Cancer Institute, Bethesda, MD, USA, *Application of comparative functional genomics to identify best-fit mouse models to study human cancer*

Abstract # 5152, He Zhou, M.D., Ph.D., The Scripps Research Institute, La Jolla, CA, USA, *A DNA-based cancer vaccine activates both innate and adaptive immunity by engaging the NKG2D receptor*

Abstract # 5231, Jerome Torrisani, Ph.D., McGill University, Montréal, PQ, Canada, *RNA binding protein AUF1 regulates DNA methyltransferase DNMT1 in the cell cycle*

Abstract # 5244, Jose I. Lopez, B.S., University of Arizona, Tucson, AZ, USA, *CD44 interactions with hyaluronan decrease the metastatic potential of breast cancer cells*

Abstract # 5246, Robert W. Cho, M.D., University of Michigan, Ann Arbor, MI, USA, *Identification of the mouse breast tumor stem cell*

Abstract # 5253, Jyotsna Pandey, M.D., Ph.D., National Cancer Institute, Rockville, MD, USA, *Modulation of tumorigenesis and tumor progression in a K-ras mutated mouse model of lung cancer in the presence of TGF- β 1 heterozygosity*

Abstract # 6092, Claudia Bredel, Ph.D., Stanford University, Stanford, CA, USA, *Whole tumor genome amplification and gene-by-gene mapping of genomic aberrations from limited sources of DNA*

Abstract # 6102, Weng-Onn Lui, Ph.D., Stanford University, Stanford, CA, USA, *A CREB3L2-PPAR γ ; fusion oncoprotein with unique activities in follicular thyroid cancer*

Abstract # 6129, Karen O. Yee, Ph.D., Beth Israel Deaconess Medical Center, Boston, MA, USA, *Role of thrombospondin-1 in a mouse model of breast cancer*

Abstract # 6130, Heath B. Acuff, B.S., Vanderbilt University, Nashville, TN, USA, *The role of host matrix metalloproteinases in lung tumor development*

Abstract # 6147, Simon Alexander Williams, Ph.D., Johns Hopkins School of Medicine, Baltimore, MD, USA, *Tumoricidal effects of a PSA-activated pore-forming toxin*

AACR-AstraZeneca Scholar-in-Training Awards

Abstract # 313, Sucharita Bandyopadhyay, Ph.D., Southern Illinois University School of Medicine, Springfield, IL, USA, *The metastasis suppressor gene Drg-1 downregulates the expression of ATF3 in prostate and breast carcinoma*

Abstract # 338, Niels Smakman, M.D., University Medical Centre Utrecht, Utrecht, The Netherlands, *Stable suppression of mutant KRAS in C26 murine colon carcinoma cells by RNA interference leads to complete loss of metastatic potential and to increased tumor immunity*

Abstract # 707, Gustavo F. Helguera, Ph.D., University of California, Los Angeles, CA, USA, *Combinations of cytokines fused to antibodies to enhance the immune response against HER2/neu expressing tumors*

Abstract # 1632, Yoonsoo Hahn, Ph.D., National Cancer Institute, Bethesda, MD, USA, *Identification of fusion genes resulting from chromosomal translocation by analyzing cancer expressed sequences tags*

Abstract # 1640, Xuting Wang, Ph.D., National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA, *In silico identification of functional polymorphisms in antioxidant response elements and their related genes in human genome*

Abstract # 2040, Jonathan Barclay Pollett, Ph.D., University of Pittsburgh, Pittsburgh, PA, USA, *Pleuropotency, a double edged sword: Mixed differentiation signals induce tumor formation in vivo*

Abstract # 2215, Carmen J. Marsit, Ph.D., Harvard School of Public Health, Boston, MA, USA, *Tobacco smoking and arsenic exposure are associated with tumor suppressor gene hypermethylation in bladder cancer*

Abstract # 2508, Sheng-Li Cai, M.D., Ph.D., UT M.D. Anderson Cancer Center, Smithville, TX, USA, *Functional interaction of TSC1 and TSC2 tumor suppressor gene products, hamartin, and tuberlin*

Abstract # 2523, Clayton C. Yates, M.S., University of Pittsburgh, Pittsburgh, PA, USA, *Characterization of prostate cancer progression by direct visualization utilizing a bioreactor*

Abstract # 2553, Yen-Ling Low, B.Sc., University of Cambridge, Cambridge, England, *Phytoestrogen exposure, polymorphisms in COMT, CYP17, CYP19, EDH17B2, ESR1, and SHBG genes, and sex hormone levels among postmenopausal women in EPIC-Norfolk*

Abstract # 2577, Jamie Keck, B.S., The Scripps Research Institute, La Jolla, CA, USA, *The effects of deregulated cyclin E on mitosis*

Abstract # 2602, Evgeny Edovitsky, M.Sc., Hebrew University of Jerusalem, Jerusalem, Israel, *Heparanase silencing averts tumor progression and inflammation*

Abstract # 2624, Palma Rocchi, Ph.D., University of British Columbia, Vancouver, BC, Canada, *Over-expression of heat shock protein 27 confers resistance androgen ablation and chemotherapy in prostate cancer through activation of Stat-3 signaling pathway*

Abstract # 2663, Bhuvanesh Dave, Ph.D., University of Arkansas, Little Rock, AR, USA, *The tumor suppressor PTEN mediates the pro-apoptotic activity of dietary genistein on mammary epithelial cells: Implications for mammary cancer protection*

Abstract # 4344, Rajesh R. Nair, Ph.D., UT M.D. Anderson Cancer Center, Houston, TX, USA, *Expression screening identifies a novel negative regulator (SM22/transgelin) of 92 kDa type IV collagenase expression*

Abstract # 4365, Clodia Osipo, Ph.D., Northwestern University, Chicago, IL, USA, *ERa and AIB-1 interact in tamoxifen-resistant breast cancer independent of ERa transcriptional activity*

Abstract # 5260, Hong Yuan, Ph.D., Duke University Medical Center, Durham, NC, USA, *(64)Cu-ATSM microPET imaging of tumor hypoxia in animal tumor models: Comparison with hypoxia immunostaining*

Abstract # 6104, Siwen Hu, M.D., Ph.D., Children's Hospital Los Angeles, Los Angeles, CA, USA, *Systemic targeted EWS-FLI1 siRNA abrogates growth of metastases in a murine Ewing's tumor model*

Abstract # 6107, Despina Siolas, B.S., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA, *Synthetic shRNAs as highly potent RNAi triggers*

Abstract # 6118, Kexiao Guo, M.S., University of Arizona, Tucson, AZ, USA, *In vitro and in vivo footprinting of the promoter region of the human vascular endothelial growth factor gene is consistent with G-quadruplex formation*

Abstract # 6131, Scott F. Winter, B.S., Fred Hutchinson Cancer Research Center, Seattle, WA, USA, *Activation of FGFR1 in vivo differentially modulates the expression of Ang1 and Ang2 while inducing angiogenesis in the mouse prostate*

AACR-Bristol-Myers Squibb Oncology Scholar-in-Training Awards

Abstract # 372, Lei Jia, M.S., New York University, New York, NY, USA, *Structural properties of spiroiminodihydantoin DNA lesions*

Abstract # 1596, Michael J. Martin, Ph.D., National Cancer Institute, Rockville, MD, USA, *Circulating levels of IGF-1, IGF-2, and IGFBP-3 and prevalence of advanced colorectal adenoma*

Abstract # 1624, Wei Hung Kuo, B.S., University of British Columbia, Vancouver, BC, Canada, *ING family members promote chromatin relaxation for nucleotide excision repair of UV-induced DNA lesions*

Abstract # 1671, John A. Curtin, Ph.D., UCSF Cancer Center, San Francisco, CA, USA, *Frequent copy number increase of CCND1 or CDK4 in melanomas without mutations in BRAF and RAS genes*

Abstract # 1678, Clark C. Chen, M.D., Ph.D., Dana-Farber Cancer Institute, Boston, MA, USA, *The Fanconi Anemia (FA) pathway confers cellular resistance to the chemotherapeutic agent 1,3-Bis(2-Chloroethyl)-1-Nitrosourea (BCNU)*

Abstract # 2576, Alex C. Minella, M.D., Fred Hutchinson Cancer Research Center, Seattle, WA, USA, *Ras activity regulates cyclin E degradation by the Fbw7 pathway*

Abstract # 2586, Kaori Sasai, Ph.D., UT M.D. Anderson Cancer Center, Houston, TX, USA, *A novel chromosomal passenger protein Aurora-C kinase can complement Aurora-B kinase function and induce stabilization of INCENP via phosphorylation*

Abstract # 2650, Julien Taieb, M.D., Ph.D., Pitié Salpêtrière Hospital, Paris, France, *Dendritic cell derived-exosomes boost effector CD8+ T cells in the absence of tumor induced-T regulatory cells: Synergistic antitumor effects of cyclophosphamide and exosome-based vaccines*

Abstract # 2665, Sunga Choi, Ph.D., University of Pittsburgh Medical School, Pittsburgh, PA, USA, *Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer chemopreventive agent*

Abstract # 2819, Matthias Sommer, M.D., Johns Hopkins School of Medicine, Baltimore, MD, USA, *p63 overexpression induces downregulation of Sirt1 and accelerated aging phenotypes in the mouse*

Abstract # 5258, Vania E. Kenanova, B.S., City of Hope & University of California, Los Angeles, CA, USA, *Engineered anti-CEA scFv-Fc antibody fragments tailored for pharmacokinetic and imaging properties*

Abstract # 6095, Min Yan, M.D., Ph.D., Case Western Reserve University, Cleveland, OH, USA, *15-hydroxyprostaglandin dehydrogenase is a TGF- β induced suppressor of human colorectal cancer*

Abstract # 6117, Diana Vradii, M.D., University of Massachusetts Medical School, Worcester, MA, USA, *Impaired intranuclear trafficking of AML1 causes transformation-coupled arrest of myeloid maturation*

Abstract # 6175, Sung-Hyung Lee, Ph.D., The Scripps Research Institute, La Jolla, CA, USA, *Endoglin (CD105) is an effective target for an oral DNA vaccine against breast cancer*

Abstract # 6180, Peter Attia, M.D., National Cancer Institute, Bethesda, MD, USA, *Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-CTLA-4*

AACR-Busch Scholar-in-Training Awards

Abstract # 2578, Feng Liu, Ph.D., University of California, Irvine, CA, USA, *Phosphorylation of CtIP by ATM regulates its own expression and activates both G1/S and G2/M checkpoints*

Abstract # 2593, Diego F. Calvisi, M.D., Ph.D., National Cancer Institute, Bethesda, MD, USA, *Combined silencing of Ras and Jak/Stat inhibitors results in constitutive activation of Ras and Jak/Stat pathways in human hepatocellular carcinoma*

Abstract # 3215, Heather J. Baer, Sc.D., Brigham and Women's Hospital, Boston, MA, USA, *Early life factors and incidence of proliferative benign breast disease*

Abstract # 4310, Michelle Lynne Demory, B.A., University of Virginia, Charlottesville, VA, USA, *The epidermal growth factor receptor translocates to the mitochondria: Implications in mediating cellular survival*

Abstract # 4340, William Cruz, M.Sc., Princess Margaret Hospital/University of Toronto, Toronto, ON, Canada, *Absence of TIMP-3 enhances metastatic dissemination to multiple organs*

Abstract # 4351, Michael VanSaun, Ph.D., Vanderbilt University, Nashville, TN, USA, *Differential detection of growth promoting proteins after MMP-7 expression in a model of mammary tumor development*

Abstract # 5222, Yoshimasa Saito, M.D., Ph.D., USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA, *Induction of microRNA-127 by DNA demethylation and histone deacetylase inhibition in human cells*

Abstract # 5821, Ute Nöthlings, Dr.P.H., Cancer Research Center of Hawaii, Honolulu, HI, USA, *Meat intake increases the risk for pancreatic cancer: The Multiethnic Cohort*

Abstract # 6174, Joerg A. Krueger, M.D., The Scripps Research Institute, La Jolla, CA, USA, *A DNA vaccine against tumor stromal antigen FAP boosts chemotherapy leading to tumor rejection*

AACR-GlaxoSmithKline Outstanding Clinical Scholars

Fore promising young cancer researchers who are the authors of outstanding proffered papers related to clinical research.

Abstract # 705, Kellie Charles, Ph.D., Queen Mary's School of Medicine and Dentistry, London, England, *Biological activity of infliximab, an anti-TNF- α monoclonal antibody, in the tumor microenvironment of advanced epithelial ovarian patients*

Abstract # 1587, Matteo Lazzeroni, M.D., European Institute of Oncology, Milan, Italy, *Effect of transdermal estradiol and oral conjugated estrogen on markers of hemostasis and cardiovascular risk in a retinoid-placebo chemoprevention trial*

Abstract # 1592, Catherine Fang-Yeu Poh, D.D.S., Ph.D., BC Cancer Agency, Vancouver, BC, Canada, *Identification of clinically occult disease in oral cancer patients in the operating room (OR): A real-time application of fluorescence visualization*

Abstract # 1593, Takashi Aoi, M.D., Kyoto University, Kyoto, Japan, *The risk of subsequent development of gastric cancer after endoscopic treatment for gastric epithelial neoplasia*

Abstract # 2138, Naomi Quinton, Ph.D., University of Leeds, Leeds, England, *Differential expression of estrogen receptor α , Ki-67 and Bcl-2 in endometrial biopsies from women treated with Anastrozole and Tamoxifen*

Abstract # 2139, Anieta M. Sieuwerts, B.S., Erasmus MC, University Medical Center, Rotterdam, The Netherlands, *How ADAM-9 and ADAM-11 differentially from estrogen-receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: A retrospective study*

Abstract # 2655, Brian Gill Barnett, M.D., Tulane University School of Medicine, New Orleans, LA, USA, *Depleting regulatory T cells is associated with improved immunity and tumor clearance in human cancer*

Abstract # 3448, Koji Abe, M.D., Ph.D., University of Pittsburgh, Pittsburgh, PA, USA, *Antitumor activity human papillomavirus Type 16 E7-specific T cells in patients with virally infected squamous cell carcinoma of the head and neck (SCCHN)*

Abstract # 5060, Belen Rubio-Viqueira, M.D., Johns Hopkins University, Baltimore, MD, USA, *Novel in vivo model for drug development in pancreas cancer*

Abstract # 5153, Yunping Luo, M.D., Ph.D., The Scripps Research Institute, La Jolla, CA, USA, *A novel stress protein, Legumain, is a target for a genetic vaccine against breast cancer*

Abstract # 6166, Jan Stoehlmacher, M.D., University of Hamburg, Hamburg, Germany, *Impact of glutathione S-transferase (GST) P1, M1 and T1 polymorphisms on clinical outcome to Cisplatin/5-Fluorouracil chemotherapy in patients with advanced gastric cancer*

AACR-ITO EN, Ltd. Scholar-in-Training Awards

For presenters of meritorious proffered papers who reside in Asian countries.

Abstract # 248, Kuen-Tyng Lin, M.S., National Health Research Institutes, Taipei, Taiwan Republic of China, *Novel effect of trichostatin A, a histone deacetylase inhibitor, treatment enhances cell migration in human hepatocellular carcinoma cell lines*

Abstract # 314, Takeshi Tsuchiya, M.D., The University of Tokyo, Tokyo, Japan, *Targeting Id1 and Id3 inhibits peritoneal metastasis of gastric cancer*

Abstract # 320, Chang-Han Chen, Ph.D., National Health Research Institutes, Miaoli, Taiwan Republic of China, *Molecular cloning and characterization of FLJ10540, a novel gene upregulated in hepatocellular carcinoma*

Abstract # 355, Mariko Tomita, M.D., Ph.D., University of the Ryukyus, Okinawa, Japan, *Activation of β -catenin signaling by HTLV-1 transforming protein Tax*

Abstract # 573, Zhong-xin Lu, M.S., Central South University, Changsha, Hunan, China, *Deoxyribozymes targeted to EBV-LMP1 mRNA induce apoptosis and enhance radiosensitivity in LMP1-positive cells*

Abstract # 750, Joydeb Kumar Kundu, M.S., Seoul National University, Seoul, Republic of Korea, *Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF- κ B in mouse skin in vivo: I κ B Kinase- β and mitogen-activated protein kinases as potential targets*

Abstract # 883, David Chi-leung Lam, M.R.C.P., University of Hong Kong, Hong Kong Special Administrative Region of China, *Expression profiling in lung adenocarcinomas with or without epidermal growth factor receptor (EGFR) gene mutation at exons 18-21 reveals expression signatures related to the EGFR pathway*

Abstract # 1666, Issan Y. S. Tam, B.Sc., University of Hong Kong, Hong Kong Special Administrative Region of China, *EGFR mutations are prevalent and independent from K-RAS mutations in lung adenocarcinomas from non-smokers*

Abstract # 1677, Muh-Hwa Yang, M.D., Taipei Veterans General Hospital, Taipei, Taiwan Republic of China, *Increased NBS1 expression is a poor prognostic marker of head and neck cancer and overexpression of NBS1 promotes transformation through the activation of Akt*

Abstract # 1912, Phyu Phyu Aung, M.B.B.S., Hiroshima University, Hiroshima, Japan, *Screening of cancer specific genes and identification of MIA as a cancer specific gene and prognostic indicator in gastric cancer*

Abstract # 2472, Jeong-Sang Lee, M.S., Seoul National University, Seoul, Republic of Korea, *Chemopreventive effects of a specific COX-2 inhibitor (Celecoxib) and a novel HDAC inhibitor (SK-7041) on azoxymethane-initiated and dextran sulfate sodium-promoted mouse colon carcinogenesis*

Abstract # 2496, Ryohei Katayama, M.S., University of Tokyo, Tokyo, Japan, *Cellular FLIP inhibits β -catenin ubiquitylation and enhances Wnt signaling*

Abstract # 2575, Eiji Tanaka, M.D., Kyoto University, Kyoto, Japan, *The role of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma*

Abstract # 2653, Toru Hiura, M.D., Niigata University, Niigata, Japan, *CD62L^{high} CD4⁺CD25⁺ regulatory T cells primed in tumor-draining lymph nodes abrogate antitumor efficacy of effector T cells via B7-2 / CTLA-4 T-T interaction*

Abstract # 2697, Min-Goo Lee, Ph.D., Korea University, Seoul, Republic of Korea, *XAF1 is a direct transcription target of p53 that potentiates p53-mediated apoptosis*

Abstract # 3552, Natini Jinawath, M.D., University of Tokyo, Tokyo, Japan, *Comparison of gene-expression profiles between liver fluke- and non-liver fluke-associated intrahepatic cholangiocarcinomas using a genome-wide cDNA microarray*

Abstract # 3561, Amit Aggarwal, M.S., National Cancer Centre/National University of Singapore, Singapore, *Topological and functional discovery in gastric cancer gene coexpression network*

Abstract # 4054, Kyoung-Ho Lee, M.P.H., Seoul National University College of Medicine, Seoul, Republic of Korea, *Stability of urinary malondialdehyde in room temperature over 16 hours*

Abstract # 4314, Takamichi Hosaka, M.D., Showa University, Tokyo, Japan, *Active mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl ubiquitin ligase*

Abstract # 4393, Toshiyuki Shimada, M.D., Keio University School of Medicine, Tokyo, Japan, *Development of targeted therapy with paclitaxel incorporated in EGF-conjugated nanoparticle*

Abstract # 4461, Il-Jin Kim, D.V.M., Ph.D., Seoul National University, Seoul, Republic of Korea, *Development of a BRAF oligonucleotide microarray and its application in competitive DNA hybridization (CDH): Mutation detection of multiple samples by CDH-based microarray analysis*

Abstract # 4586, Naohiro Tsuyama, M.S., Yamaguchi University, Ube, Japan, *Lipid raft translocation of CD45RO, RB but not RA is significant for IL-6 responsive proliferation of myeloma cells*

Abstract # 4595, Jun Inoue, Ph.D., Tokyo Medical and Dental University, Tokyo, Japan, *High-throughput screening of methylated DNA sequences at Ip35-p36 in neuroblastoma by using BAC array-based MCA method (BAMCA)*

Abstract # 5298, Noriyuki Omura, M.D., Tohoku University School of Medicine, Sendai, Japan, *A novel E1A-E1B mutated adenovirus with modified fiber demonstrates effective tumor regression for pancreatic cancer therapy in vivo*

Abstract # 5537, Yihua Wang, Ph.D., Chinese Academy of Medical Sciences, Beijing, China, *Overexpression of EBI in human esophageal squamous cell carcinoma (ESCC): Promoting cellular growth probably by activating β -catenin/TCF pathway*

Abstract # 5574, Wai Kei Kwok, M.Phil., The University of Hong Kong, Hong Kong Special Administrative Region of China, *Upregulation of TWIST in prostate cancer and its implication as a therapeutic target*

Abstract # 6177, Shigehisa Kitano, M.D., Mie University School of Medicine, Tsu, Mie, Japan, *Cellular and humoral immune responses in patients vaccinated with HER2 protein combined with a novel nanoparticle antigen delivery system of cholesteryl hydrophobized polysaccharide (CHP-HER2)*

MEG/AACR Scholar-in-Training Awards

For meritorious proffered papers in molecular epidemiology.

Abstract # 2558, Yawei Zhang, M.D., Ph.D., National Cancer Institute, Rockville, MD, USA, *Polymorphisms in cell cycle pathway genes and risk of non-Hodgkins lymphoma*

Abstract # 4376, Meghan A. McSorley, M.P.H., Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, *A collaborative study of the association between C-reactive protein concentrations and subsequent ovarian cancer risk*

Abstract # 4384, Shehnaz K. Hussain, M.S., University of Washington, Seattle, WA, USA, *Interleukin-2 and interleukin-2 receptor gamma gene polymorphisms, cigarette smoking, and risk of squamous cell cervical cancer*

AACR-Merck Scholar-in-Training Awards

Abstract # 804, Jennifer L. Brace, B.S., Johns Hopkins University, Baltimore, MD, USA, *The saccharomyces cerevisiae survival factor, SVF1, plays a role in sphingoid base signaling and survival*

Abstract # 1643, Jia Huang, B.S., University of Pennsylvania, Philadelphia, PA, USA, *Identification of common deletions in breast cancers from non-BRCA1/BRCA2 families using array-based comparative genomic hybridization*

Abstract # 1687, Robert C.A.M. van Waardenburg, Ph.D., St. Jude Children's Research Hospital, Memphis, TN, USA, *SUMO-conjugation regulates cell sensitivity to genotoxic stress*

Abstract # 1703, Elizabeth Alli, M.S., University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA, *Partial restoration of p53 tumor suppressor function by siRNA to stathmin*

Abstract # 2517, Cristina Nogueira, B.S., Dana-Farber Cancer Institute, Boston, MA, USA, *Molecular dissection of melanoma-relevant genes and pathways*

Abstract # 2522, Yori-hisa Imanishi, M.D., Ph.D., University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA, *Angiopoietin-2 promotes MCF-7 breast cancer cell metastases by inducing epithelial-mesenchymal transition (EMT) through the β 1 integrin-mediated signaling pathway*

Abstract # 2527, Weigang Wang, Ph.D., Albert Einstein College of Medicine, Bronx, NY, USA, *Effect of LIM-kinase 1 on cancer invasion and metastasis*

Abstract # 2579, Changxian Shen, Ph.D., St. Jude Children's Research Hospital, Memphis, TN, USA, *The TOR pathway regulates S phase progression in response to DNA damage and replication stress*

Abstract # 2585, Evan C. Osmundson, B.S., University of Illinois, Chicago, IL, USA, *TGF- β regulates β -TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner*

Abstract # 2594, Martijn P.J.K. Lolkema, M.D., University Medical Center Utrecht, Utrecht, The Netherlands, *VHL is a target of Wnt signaling and may regulate the angiogenic switch in colorectal carcinoma*

Abstract # 2603, Kathryn L. Schwertfeger, Ph.D., Baylor College of Medicine, Houston, TX, USA, *Early FGFR-mediated induction of the inflammatory response in breast cancer progression*

Abstract # 2619, Eunmi Park, M.S., UT M.D. Anderson Cancer Center, Smithville, TX, USA, *IKK α coordinates with RAS to switch well-differentiated papillomas to poorly differentiated malignant carcinomas in skin*

Abstract # 2622, Yakov Chudnovsky, B.A., Stanford University, Stanford, CA, USA, *Induction of invasive human melanocytic neoplasia by defined genetic elements*

Abstract # 2662, Kristin A. Waite, Ph.D., The Ohio State University, Columbus, OH, USA, *Phytoestrogen stimulation increases PTEN protein*

Abstract # 2666, Melinda C. Myzak, B.A., Oregon State University, Corvallis, OR, USA, *In vivo inhibition of histone deacetylase by sulforaphane*

Abstract # 3575, Hanlee Ji, M.D., Stanford University, Stanford, CA, USA, *The study of DNA repair in colon neoplastic development: a comparative-functional genomics approach*

Abstract # 4063, Brock C. Christensen, B.S., Harvard School of Public Health, Boston, MA, USA, *Mutation spectra of p53 in a population based case series of non-melanoma skin cancer*

Abstract # 5306, Li Yang, Ph.D., Vanderbilt-Ingram Cancer Center, Nashville, TN, USA, *Prostaglandin receptor EP2 but not EP4 inhibits DC migration in tumor-bearing hosts*

Abstract # 5678, Sung-Hyeok Hong, D.V.M., Ph.D., National Cancer Institute, Rockville, MD, USA, *The membrane-cytoskeleton linker ezrin provides a survival advantage to metastatic osteosarcoma cells that reach in the lung*

Abstract # 6116, Jeffery J.M. Cowger, B.Sc., University of Western Ontario, London, ON, Canada, *The putative oncogene ZABC1 (ZNF217) is a transcriptional repressor that interacts with CtBP*

Abstract # 6119, Kathryn A. O'Donnell, B.S., Johns Hopkins School of Medicine, Baltimore, MD, USA, *Transferrin Receptor 1, a direct c-Myc target, is necessary for cell-cycle progression and stimulates cellular proliferation under limiting conditions*

Abstract # 6140, Marta Guix, M.D., Vanderbilt University, Nashville, TN, USA, *Short course of EGF receptor tyrosine kinase inhibitor erlotinib (OSI-774, 'Tarceva') reduces tumor cell proliferation and active MAP kinase in situ in untreated operable breast cancers: A strategy for patient selection into Phase II trials with signaling inhibitors*

AACR-National Foundation for Cancer Research-Chemistry in Cancer Research Scholar-in-Training Awards
For meritorious proffered papers in chemistry.

Abstract # 371, Charles Gerhard Knutson, B.S., Vanderbilt University, Nashville, TN, USA, *Oxidative metabolism of an endogenously produced DNA adduct, M1dG: A novel approach to biomarker discovery*

Abstract # 373, Tao Jiang, Ph.D., Massachusetts Institute of Technology, Cambridge, MA, USA, *Deoxyribose oxidation in DNA leads to the formation of N6-formyllysine residues in histone proteins*

Abstract # 378, Renée S. Mijal, M.P.H., University of Minnesota, Minneapolis, MN, USA, *Sequence context affects the repair of the tobacco-specific nitrosamine adduct O⁶-pyridyloxobutylguanine by human O⁶-alkylguanine-DNA alkyltransferase variants*

Abstract # 2114, Lida Oum, M.S., New York University, Brooklyn, NY, USA, *Comparisons of replication of DNA templates with single (+)-trans-B[a]P-Gua lesions catalyzed by thermophilic A-family and Y-family polymerases*

Abstract # 5267, Fang Li, Ph.D., Duke University Medical Center, Durham, NC, USA, *Noninvasive imaging of Hypoxia-inducible Factor 1a (HIF-1a) level during radiation therapy of cancer*

AACR-Pezcoller Foundation Scholar-in-Training Awards

For presenters of meritorious proffered papers who reside in Europe.

Abstract # 1641, Daniëlle Meijer, M.Sc., Erasmus MC, University Medical Center, Rotterdam, The Netherlands, *Functional screen for genes responsible for tamoxifen resistance of human breast cancer cells*

Abstract # 2526, Laura Rosanò, Ph.D., Regina Elena National Cancer Institute, Rome, Italy, *Endothelin-1/endothelin A receptor pathway is critical for epithelial-mesenchymal transition and metastasis in ovarian carcinoma progression*

Abstract # 2599, Maurice Reimann, Ph.D., Charité-Universitätsmedizin Berlin, CVK, Berlin, Germany, *ATM attenuates Myc-driven lymphomagenesis by sensing oncogene-induced DNA damage in vivo*

Abstract # 2955, Marco Mazzone, M.S., Consorzio Mario Negri Sud, Santa Maria Imbaro (Chieti), Italy, *Morpho-functional characterization of the intracellular activation compartment of the integral membrane type 1 matrix metalloprotease*

Abstract # 4312, Leonard Girnita, M.D., Ph.D., Karolinska Institute, Stockholm, Sweden, *Twin function of MDM 2 mediated ubiquitination of IGF-1R: Downregulation and signal activation*

Abstract # 4403, Guy E. S. Faust, M.B.B.S., University of Leicester, Leicester, England, *Oral administration of resveratrol in humans: Evaluation of plasma and urine levels*

Abstract # 6141, Angelika B. Riemer, M.D., Ph.D., Medical University of Vienna, Vienna, Austria, *Computerized mimotope surface scan identifies the cetuximab epitope on EGFR*

AACR-sanofi-aventis Scholar-in-Training Awards

Abstract # 930, Ido Wolf, M.D., Cedars-Sinai Medical Center, Los Angeles, CA, USA, *Unmasking of epigenetic silencing of PTCH and analysis of its expression and activities in breast cancer*

Abstract # 1621, George Poulogiannis, M.Sc., University of Cambridge, Cambridge, England, *1Mb resolution array-CGH identifies small chromosome aberrations in chromosome unstable and microsatellite unstable colorectal cancers*

Abstract # 1628, Yuxun Wang, M.D., Ph.D., Albert Einstein College of Medicine, Bronx, NY, USA, *A missense mutation in replication protein A1 acts as a genetic modifier of p53 tumorigenesis*

Abstract # 1660, Andreas Rimner, M.D., Memorial Sloan-Kettering Cancer Center, New York, NY, USA, *Detection of γ H2AX foci as a marker for repair of radiation-induced DNA damage in vitro and in vivo*

Abstract # 1709, Brunilde M. Gril, M.S., University of Paris, Paris, France, *SH3-Grb2 ligand inhibits HER2-dependent growth of cancer cells, increases docetaxel-induced apoptosis, and enhances docetaxel anti-tumor effects in human cancer xenografts*

Abstract # 1796, Yaron Pereg, B.Sc., Tel Aviv University, Tel Aviv, Israel, *Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation following to DNA damage*

Abstract # 2200, Chu-Ling Yu, Sc.D., Harvard School of Public Health, Boston, MA, USA, *Residential exposure to petrochemicals and risk of leukemia: Using GIS tools to estimate individual residential exposure levels*

Abstract # 2231, Ann M. Madsen, M.P.H., Columbia University, New York, NY, USA, *Plasma alpha-tocopherol and oxidative damage in the white blood cells of smokers*

Abstract # 2438, Xiaoling Shen, B.S., University of Nebraska Medical Center, Omaha, NE, USA, *Mechanisms of interferon gamma anti-tumor effects against MUC1 expressing tumors*

Abstract # 2512, Kurt A. Krummel, Ph.D., The Salk Institute, La Jolla, CA, USA, *A p53 mouse model with C-terminal lysine mutations is viable, but shows altered target gene transactivation*

Abstract # 2581, Kongming Wu, Ph.D., Georgetown University, Washington, DC, USA, *DACH1 inhibits breast cancer cell growth and invasion through down-regulating cyclin D1 kinase activity*

Abstract # 4266, Tzu-Hsuan (Leon) Huang, M.S., University of California, Los Angeles, CA, USA, *Anti-human HER2/neu TNF α : an agonistic antibody inducing HER2/neu activation in vitro*

Abstract # 4271, Elizabeth Roman, M.D., Columbia University, New York, NY, USA, *CD22 and CD74 expression in B-precursor acute lymphoblastic leukemia (pre-B ALL) and significant cytotoxicity of anti-CD22 and anti-CD74 antibodies: Implications for targeted immunotherapy*

Abstract # 4477, Jingrui Jiang, Ph.D., Dana-Farber Cancer Institute, Boston, MA, USA, *Identification and characterization of a novel activating mutation in the extracellular domain of the FLT3 Tyrosine Kinase in ALL*

Abstract # 5800, Matthew B. Schabath, Ph.D., UT M.D. Anderson Cancer Center, Houston, TX, USA, *Dietary phytoestrogens and lung cancer risk*
Abstract # 6100, Minjung Kim, Ph.D., Dana-Farber Cancer Institute, Boston, MA, USA, *Identification of novel candidate melanoma oncogene by comparative oncogenomics*

Avon Foundation-AACR International Scholar-in-Training Grants

For presenters from countries in Eastern Europe, Latin America, Africa, the Middle East, and Asia where opportunities for scientific advancement are limited and whose proffered papers relate to breast cancer or other female cancers.

Abstract # 106, Patricia Bortman Rozenchan, Ph.D., Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, *Differential gene expression profile of fibroblasts originated from breast cancer as compared to those derived from benign disease and after coculture with normal epithelial mammary cells*

Abstract # 342, Marina Simian, Ph.D., Institute of Oncology Angel H. Roffo, Buenos Aires, Argentina, *Involvement of proteolytic activity in the response of an estrogen-dependent mammary tumor to endocrine therapy*

Abstract # 357, Albana Gattelli, M.S., University of Buenos Aires, Buenos Aires, Argentina, *Progression of pregnancy-dependent MMTV-induced mammary tumors occurs by selection of pre-existent insertional events*

Abstract # 1132, Hyun-Jun Kim, M.S., Hanyang University, Seoul, Republic of Korea, *Id-1 induces tumor angiogenesis in human breast cancers by stabilizing HIF-1 α protein*

Abstract # 1285, Romina P. Carnevale, M.S., Institute of Biology and Experimental Medicine (IBYME), CONICET, Buenos Aires, Argentina, *Progesterone regulates proliferation and protease activity via rapid activation of MAPKs and PI-3K/Akt pathways in breast cancer cells*

Abstract # 1438, Priscilla Pui Sze Lee, Ph.D., National University of Singapore, Singapore, *Vitamin E TPGS-modified paclitaxel: Synthesis, characterizations, and in vitro activities*

Abstract # 1564, Hye-Kyung Na, Ph.D., Seoul National University, Seoul, Republic of Korea, *EGCG upregulates phase-2 detoxifying and antioxidant enzymes via the Nrf2 signaling pathway in human breast epithelial cells*

Abstract # 1609, Ji-Yeob Choi, Ph.D., Seoul National University College of Medicine, Seoul, Republic of Korea, *Haplotype of NOS3, hormone receptor status, and survival of breast cancer*

Abstract # 1867, Shenglan Cao, B.Sc., Nanyang Technological University, Singapore, *A novel hormonally-regulated protein with a tetratricopeptide repeat that is over-expressed in breast tumors*

Abstract # 1899, Theoni Leoutsakou, M.S., NCSR Demokritos, Athens, Greece, *Expression analysis and prognostic significance of SR-A1 gene, encoding for a new member of the human ser/arg-rich family of pre-mRNA splicing factors, in breast and ovarian cancer*

Abstract # 2429, Mariana Salatino, M.S., Institute of Biology and Experimental Medicine (IBYME), CONICET, Buenos Aires, Argentina, *Immunization with breast cancer cells treated with antisense oligodeoxynucleotides (AS[S]ODN) to type I insulin-like growth factor receptor (IGF-IR) induced an antitumoral effect that is mediated by a CD8 $^{+}$ -response involving Fas-FasL cytotoxic pathway*

Abstract # 3086, Cho-Hwa Liao, M.S., National Taiwan University, Taipei, Taiwan Republic of China, *Evodiamine, a constituent from Chinese herb Evodiae Fructus, exhibited anticancer effect in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo*

Abstract # 3220, Yeon Ju Kim, M.D., Seoul National University, Seoul, Republic of Korea, *Dose-dependant protective effect of lactation against breast cancer in ever-lactated women in Korea*

Abstract # 3601, Johanna R. Ledwaba, M.S., University of the Witwatersrand, Johannesburg, South Africa, *Increased levels of RbBP6 in cervical cancer suggest its involvement in carcinogenesis*

Abstract # 3689, Maria Giselle Peters, M.S., Institute of Oncology Angel H. Roffo, Buenos Aires, Argentina, *Role of Glypican-3 in the control of death and proliferation of murine mammary adenocarcinoma cells*

Abstract # 3703, Alejandro J. Urtreger, Ph.D., Institute of Oncology Angel H. Roffo, Buenos Aires, Argentina, *Different responses associated with PKC-beta-1 and PKC-epsilon overexpression in normal and tumoral mammary cell lines*

Abstract # 3724, Martin A. Krasnapolski, M.S., Institute of Oncology Angel H. Roffo, Buenos Aires, Argentina, *The interactions between luminal and myoepithelial cells determine the in vivo and in vitro malignant properties of a murine mammary tumor*

Abstract # 4147, Yeon Ho Choi, B.S., Cancer Metastasis Research Center, Seoul, Republic of Korea, *Pharmacogenomic markers predicting toxicity and response of gemcitabine in breast cancer patients*

Abstract # 4920, Kyoung-Mu Lee, M.P.H., Seoul National University College of Medicine, Seoul, Republic of Korea, *Genetic polymorphisms of NOS3 and invasive breast cancer risk*

Abstract # 5208, Ji-Youn Jung, D.V.M., Ph.D., Hanyang University, Seoul, Republic of Korea, *The anti-tumor effect of a novel adenosine receptor type A3 agonist, LJ540, in human breast cancer both in vitro and in vivo*

Abstract # 5622, Aliko Stathopoulou, Ph.D., University of Athens, Athens, Greece, *An improved real-time RT-PCR method for the quantitative determination of CK19 mRNA positive cells in peripheral blood of breast cancer patients*

Abstract # 5780, Majed S. Alokail, Ph.D., King Saud University, Riyadh, Saudi Arabia, *Induction of erbB1 and erbB2 receptors by PTHrP in breast cancer cells*

Abstract # 5781, Cecilia J. Proietti, M.S., Institute of Biology and Experimental Medicine (IBYME), CONICET, Buenos Aires, Argentina, *Progesterins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via Jak and Src-dependent mechanism in breast cancer cells*

Abstract # 5814, Sang-Ah Lee, Ph.D., National Cancer Center Research Institute, Goyong-Si, Republic of Korea, *Interactive effects of antioxidant vitamins and NOS3 genetic polymorphisms for breast cancer risk in Korean women*

Abstract # 5825, Xiao-Ning Guo, B.S., Shanghai Institute of Materia Medica, Shanghai, China, *TKI-28, a broad spectrum tyrosine kinase inhibitor with anti-tumor and antiangiogenic effect*